article thumbnail

Waters becomes first liquid chromatography column provider to receive My Green Lab ACT ecolabel certification

Express Pharma

Waters pioneered ultra performance liquid chromatography (UPLC) in 2004 with the launch of the ACQUITY UPLC Column, enabling the optimal use of sub 2-µm particles for the first time.

Packaging 107
article thumbnail

Beyond instruments: streamlining process technology implementation in biopharmaceutical manufacturing

European Pharmaceutical Review

Given that multiple work packages may often start or end together, or else take longer than others ( Figure 1 ), the introduction of new PAT requires assessment and planning by multiple departments. Food and Drug Administration (FDA), 2004. Figure 2 outlines four main topics where PAT can play an important role: (1) Industry 4.0

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

It is too early to say because we have not seen the whole package of measures yet. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2004. One of the key priorities of the EU’s strategy is to encourage innovation to solve unmet medical needs. THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION; 2006.

article thumbnail

Five potential EU regulatory changes impacting the life sciences industry in 2023

European Pharmaceutical Review

Launch of the EU pharmaceutical package The European Commission plans to commence initiatives relating to the European Pharmaceutical Strategy (strategy) with the publication of the revised EU pharmaceutical package scheduled during the first quarter of 2023.

Packaging 117
article thumbnail

Medicare Part D for LTC Pharmacy: A Refresher

Integra X Files

Industry representatives spent many hours during 2004 discussing the needs of nursing home residents and the current standards of service.

article thumbnail

Hashimoto’s and Graves’ Remission after Helicobacter Pylori Eradication

The Thyroid Pharmacist

Source: Bertalot et al, 2004). Source: Bertalot et al, 2004). MegaGuard and PyloGuard provide doses on the package. Reduction in TPO antibodies ranged from 50 to 99 percent, while reduction of TG antibodies ranged from 31 to 95 percent over the course of 17 to 22 months. (23). The five patients with Hashimoto’s and untreated H.

article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

R&D Expenditure: $7.19B Founded Year: 2004 Total Employees: ~91,573,440 Headquarters: Paris, France Market Cap: $143.9B In Nov 2021, GSK entered into a license agreement with Arrowhead to develop and commercialize Arrowhead’s RNAi therapy, ARO-HSD. R&D Expenditure: $14.6B